A newly published review in Medicine Plus establishes a comprehensive microrobotic framework to overcome the longstanding hurdles of locoregional therapy in luminal malignancies. The work, led by Prof. Xiaoyuan Ji and Prof. Yong Kang at the Advanced Medical Materials and Devices National Key Laboratory, Tianjin University, details how engineered microbe-based micro/nanorobots can revolutionize clinical intervention across gastrointestinal, gynecological, and urological cancers.
Luminal cancers—including colorectal, gastric, rectal, cervical, bladder, and peritoneal tumors—are anatomically accessible through natural orifices or intracavitary routes. However, physical accessibility rarely guarantees clinical efficacy. Dense mucus barriers, continuous luminal fluid turnover, urinary washout, tight epithelial layers, stromal scarring, hypoxia, acidosis, and immunosuppressive tumor microenvironments severely impairs the penetration, retention, and bioactivity of conventional therapeutic agents.
To address these challenges, the authors advocate for engineered microbe-based micro/nanorobots as a fundamentally superior therapeutic strategy. Unlike conventional formulations reliant on passive diffusion and transient drug exposure, these living microrobotic systems can actively navigate, adapt to and reside within hostile luminal cavities. By leveraging native microbial traits—such as self-propulsion, environmental sensing, interfacial adaptability, niche-selective colonization, and continuous biosynthesis—and combining them with synthetic biology and functional materials, researches can transform wild-type microbes into highly controllable, programmable living therapeutics.
The review categorizes this living robotic paradigm into four synergistic capabilities:
The authors emphasize that micro/nanorobot design must be strictly tailored to specific delivery routes. Oral systems require protective coatings to withstand gastric acid and digestive enzymes before colonizing the gut. Suppository-based platforms must achieve prolonged retention, mucosal adhesion, and effective tissue interaction in rectal or cervical lesions. Instillation-based systems for bladder cancer must feature active propulsion or mucosal anchoring to counteract fluid exchange, urinary washout, and rapid urinary clearance.
Ultimately, the review asserts that engineered microbial microrobotics shifts the clinical goal from mere local drug delivery toward dynamic, persistent, and autonomous disease management within the pathological niche.
Medicine Plus
Literature review